Flare Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
215 1st St Ste 150, Cambridge, Massachus...Phone Number
(857) 706-4400Website
www.flaretx.comRevenue
$5.6 MillionIndustry
About Flare Therapeutics
Flare Therapeutics Org Chart
Is Flare Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Flare Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Flare Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Flare Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Flare Therapeutics
Click to see if Flare Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Flare Therapeutics launches new products
Earning: See what the market has to say on Flare Therapeutics recently announced quarterly report
Flare Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Flare Therapeutics
Find more new buyers
Compare Similar Companies to Flare Therapeutics
Compare insights from companies similar to Flare Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Flare Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Flare Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Flare Therapeutics.
Flare Therapeutics financials insights
Gather financial insights about Flare Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$82M
Series B
$123M
Flare Therapeutics Tech Stack
A closer look at the technologies used by Flare Therapeutics
Most Recent Scoops
Flare Therapeutics News & Media
Flare Therapeutics Inc. Partners with Simplicis to Eliminate "Single-Point-of-Failure" Risks in Compound Management
By adopting Simplicis Ledger™, Flare Therapeutics replaces manual "human-babysitting" of data with automation-ready infrastructure to scale life sciences R&D. CAMBRIDGE, Mass., March 2, 2026 /PRNewswire/ -- Simplicis, a provider of modern sample and inventory management software for life...Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UCFlare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the appointment of Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer. Dr. Eck brings more than three decades of oncology drug discovery and development leadership across academia, biotechnology and large pharmaceutical companies.Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Doug Manion, M.D., FRCP (C), Chief Executive Officer and Board Member, will present a company overview at the upcoming 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:00 a.m. PT in San Francisco, CA.
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Flare Therapeutics
Based in Cambridge, MA, Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flares team has uncovered switch sites, druggable regions that are ke... Read More
